Physician profile
Anique M Bryan
NPI 1114980190
$5,727.47
in general payments reported to CMS, 2019-2025
32 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $315 · 2021: $937 · 2022: $1,086 · 2023: $603 · 2024: $973 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.70 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,280.21 | 2022-2025 | Mycarelink, Micra, Aurora Ev-Icd Mri Surescan |
| Pfizer INC. | $456.51 | 2019-2025 | |
| Boston Scientific Corporation | $451.28 | 2019-2022 | |
| Abbott Laboratories | $363.21 | 2019-2025 | Freestyle Libre 2, Navitor, Amplatzer Amulet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $333.47 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $304.91 | 2019-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $302.02 | 2019-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $293.52 | 2019-2025 | Wainua |
| Astellas Pharma US INC | $250.75 | 2019-2023 | Veozah |
| Abbvie INC. | $249.81 | 2021-2025 | |
| Amarin Pharma, INC. | $227.81 | 2019-2020 | |
| Akcea Therapeutics, INC. | $168.08 | 2019-2021 | |
| Shockwave Medical, INC | $147.80 | 2021 | |
| Impulse Dynamics (USA) INC. | $146.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.07 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $86.68 | 2024 | (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $82.89 | 2020-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $54.17 | 2021-2025 | |
| Amgen INC. | $54.13 | 2019-2023 | Otezla, Repatha |
| Baxter Healthcare | $50.17 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $47.27 | 2023 | Inpefa |
| Lilly USA, LLC | $38.14 | 2021-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $34.86 | 2024-2025 | Verquvo |
| Bridgebio Pharma, INC. | $32.88 | 2025 | Attruby |
| Atricure, INC. | $32.85 | 2023 | |
| Irhythm Technologies, INC. | $21.55 | 2024 | Zio Monitor, Zio Xt Patch |
| Sanofi-Aventis U.S. LLC | $21.53 | 2022 | |
| My01 INC. | $20.74 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.87 | 2025 | Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $16.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.82 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anique Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.